Investors considering shares of Mineralys Therapeutics Inc (MLYS), currently priced at $37.05 each, might explore alternative investment strategies, such as selling puts. Notably, the June 2026 put option at a $22.50 strike has a current bid of $1.70, offering a potential 7.6% return on the commitment, which annualizes to 16.1%.
Should Mineralys Therapeutics’ share price decline by 39.4% to exercise the put, the cost basis would be $20.80 per share after accounting for the premium received. The stock has a trailing twelve-month volatility of 97%, highlighting significant price fluctuation potential. Investors should weigh these figures against their risk appetite and market analysis before proceeding.
